The European life science sector is entering a phase of profound and systemic regulatory changes that will significantly impact research, innovation development, and commercialization in the coming years. On January 29, 2026, our colleague, Zofia Kubic had the opportunity to participate in the LifeScience Kraków Cluster meeting, representing the KG Legal Kiełtyka Gładkowski law firm, a member of the cluster. During the meeting, key European Union initiatives were discussed, setting a new direction for pharmaceutical, biotechnology, and medical device manufacturers.
On January 15, 2026, our colleague, Zofia Kubic, had the opportunity to participate in the LifeScience Kraków Cluster meeting, representing the KG Legal Kiełtyka Gładkowski law firm, a member of the cluster. The meeting was held as a Cluster Breakfast and was concise and strategic in nature, focusing primarily on the organization’s development plans for the coming year and beyond. Additionally, 2026 was considered a special year in the Cluster’s history, marking its 20th anniversary.
During the meeting, it was emphasized at the outset that the Cluster would continue its activities in its existing key areas. These included: bioeconomy, healthcare technology, innovative therapies and medical devices, diagnostics, and preventive healthcare. Emphasizing these areas was intended to confirm the continuity of the Cluster’s strategy and further direct its activities, including through the development of roadmaps and the development of cooperation between partners operating in these sectors.
KIEŁTYKA GŁADKOWSKI KG LEGAL participated in the conference “Longevity Biotech: Investing in a healthier future”. As part of its life science specialisation, our biotech and pharma lawyers offer comprehensive legal services to its clients in many areas of law, including extensive legal services to companies operating in the longevity biotech sector and biotech companies engaged in life extension and human health. Within this specialism our law firm offers assistance in respect of trademark protection and patent issues, regulatory law, certification, contractual, and litigation and arbitration issues. At KG Legal, we know that a key role in the biotechnology sector is innovation and responsiveness to changing market needs. Therefore, we offer our clients a proactive approach, flexibility and efficiency in action. All these qualities of our firm make us recognized as one of the leading law firms in Poland and the world, especially in the field of cross-border specialization and knowledge.
Covering 13 practice areas and 17 jurisdictions – from Albania to Ukraine – the awards were grounded in Legal 500’s independent research, ensuring credibility and impartial recognition across the region.
We would like to share the information that the leader of the Legal 500 CEE Awards 2025 (WARSAW, Thursday 16 October 2025 | The The Westin Warsaw) in the pharma and biotech law (LIFESCIENCE AND HEALTHCARE) category was selected Małgorzata Kiełtyka, partner of KG LEGAL Kiełtyka Gładkowski – Professional Partnership. Attorney Law Firm.
On September 11th, we had the pleasure of participating in an event organized by LifeScience Cluster on the application of artificial intelligence in healthcare. The webinar began with an explanation of the very concept of AI, which is controversial and riddled with myths. A key element of AI is machine learning. It involves creating predictions based on previous data. Within machine learning, deep learning, a model based on neural networks, was developed. The difference between traditional machine learning and deep learning lies primarily in the number of neural network layers. These enable the recognition of increasingly complex relationships. The concept of data science, which lies between artificial intelligence and data analysis, was also mentioned. It is the art of combining data with practice. This allows for the automation of many processes and better decision-making.
